Michael Barnett
Michael Barnett
The University of Sydney / Brain and Mind Centre
Verified email at sydney.edu.au
TitleCited byYear
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ...
New England Journal of Medicine 367 (12), 1098-1107, 2012
Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion
MH Barnett, JW Prineas
Annals of Neurology 55 (4), 458-468, 2004
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis
CG Bien, A Vincent, MH Barnett, AJ Becker, M Blümcke, F Graus
Brain, 2012
Multiple sclerosis: distribution of inflammatory cells in newly forming lesions
APD Henderson, MH Barnett, JDE Parratt, JW Prineas
Annals of neurology 66 (6), 739-753, 2009
Immunopathology of secondary‐progressive multiple sclerosis
JW Prineas, EE Kwon, ES Cho, LR Sharer, MH Barnett, EL Oleszak, ...
Annals of neurology 50 (5), 646-657, 2001
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
V Devonshire, Y Lapierre, R Macdonell, C Ramo‐Tello, F Patti, ...
European journal of neurology 18 (1), 69-77, 2010
The evidence for a role of B cells in multiple sclerosis
G Disanto, JM Morahan, MH Barnett, G Giovannoni, SV Ramagopalan
Neurology 78 (11), 823-832, 2012
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects
A Minagar, MH Barnett, RHB Benedict, D Pelletier, I Pirko, MA Sahraian, ...
Neurology 80 (2), 210-219, 2013
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
EK Mathey, SB Park, RAC Hughes, JD Pollard, PJ Armati, MH Barnett, ...
J Neurol Neurosurg Psychiatry 86 (9), 973-985, 2015
The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion
MH Barnett, APD Henderson, JW Prineas
Multiple sclerosis 12 (2), 121-132, 2006
CNS demyelination and quadrivalent HPV vaccination
I Sutton, R Lahoria, IL Tan, P Clouston, MH Barnett
Multiple Sclerosis Journal 15 (1), 116-119, 2009
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
S Ramanathan, SW Reddel, A Henderson, JDE Parratt, M Barnett, ...
Neurology-Neuroimmunology Neuroinflammation 1 (4), e40, 2014
The pathology of multiple sclerosis: a paradigm shift
MH Barnett, I Sutton
Current opinion in neurology 19 (3), 242-247, 2006
A follow up study of patients with paraneoplastic neurological disease in the United Kingdom
PM Candler, PE Hart, M Barnett, R Weil, JH Rees
Journal of Neurology, Neurosurgery & Psychiatry 75 (10), 1411-1415, 2004
Fingolimod after natalizumab and the risk of short-term relapse
VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ...
Neurology 82 (14), 1204-1211, 2014
Fingolimod after natalizumab and the risk of short-term relapse
VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ...
Neurology 82 (14), 1204-1211, 2014
Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy
MH Barnett, JW Prineas, ME Buckland, JDE Parratt, JD Pollard
Multiple Sclerosis Journal, 2011
Immunoglobulins and complement in postmortem multiple sclerosis tissue
MH Barnett, JDE Parratt, ES Cho, JW Prineas
Annals of neurology 65 (1), 32-46, 2009
Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy
MH Barnett, JD Pollard, L Davies, JG McLeod
Muscle & Nerve: Official Journal of the American Association of …, 1998
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
The system can't perform the operation now. Try again later.
Articles 1–20